The CC-115 shows preclinical RCC activity via DNA-PK/mTOR blockade and has phase I safety data in mixed solid tumors, while peposertib is being explored preclinically and in early trials (including combinations with ATR inhibitors), with an RCC-relevant rationale but no clinical efficacy signal in RCC yet [98]. Here, MTOR is linked to renal cell carcinoma.